0001193125-15-393732.txt : 201512030001193125-15-393732.hdr.sgml
: 2015120320151203080056ACCESSION
NUMBER:0001193125-15-393732CONFORMED SUBMISSION TYPE:8-KPUBLIC
DOCUMENT COUNT:44CONFORMED PERIOD OF REPORT:20151203ITEM
INFORMATION:Regulation FD DisclosureITEM INFORMATION:Financial
Statements and ExhibitsFILED AS OF DATE:20151203DATE AS OF
CHANGE:20151203
FILER:
COMPANY DATA:COMPANY CONFORMED NAME:LEMAITRE VASCULAR INCCENTRAL
INDEX KEY:0001158895STANDARD INDUSTRIAL CLASSIFICATION:SURGICAL
& MEDICAL INSTRUMENTS & APPARATUS [3841]IRS
NUMBER:000000000FISCAL YEAR END:1231
FILING VALUES:FORM TYPE:8-KSEC ACT:1934 ActSEC FILE
NUMBER:001-33092FILM NUMBER:151266263
BUSINESS ADDRESS:STREET 1:43 SECOND
AVECITY:BURLINGTONSTATE:MAZIP:01803BUSINESS PHONE:781-221-2266
MAIL ADDRESS:STREET 1:43 SECOND
AVECITY:BURLINGTONSTATE:MAZIP:01803
8-K1d24041d8k.htmFORM 8-K
Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENTREPORT
PURSUANT TO SECTION13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December 3,
2015
LeMaitre Vascular, Inc.
(Exact Name of Registrant as Specified in Its
Charter)
Delaware001-3309204-2825458
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
43 Second Avenue
Burlington, Massachusetts01803
(Address of Principal Executive Offices)(Zip
Code)
(781) 221-2266
(Registrants Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under anyof the following provisions:
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Item7.01. Regulation FD Disclosure.
On December3, 2015, LeMaitre Vascular, Inc. (the Company) is
hosting an investor and analyst meeting (AnalystDay) beginning at
8:30 a.m. ET at Ruths Chris Steak House, located at 148 W. 51st
St., New York, New York. During this meeting, management is
providing investors and analysts with anoverview of the Companys
business, positioning, overall corporate strategy and future growth
opportunities as well as reiterating the Companys financial outlook
for the fourth quarter and full year 2015 previously announced
onOctober27, 2015. The Analyst Day presentation materials are
attached hereto as Exhibit 99.1 and incorporated herein by
reference.The Company may use these materials at one or more
subsequent conferences or meetings with analysts andinvestors. The
presentation materials will also be available online at
www.lemaitre.com/investor as of December3, 2015.
Theinformation contained in this report, including the exhibit
attached hereto, is being furnished and shall not be deemed filed
for any purpose, and shall not be deemed incorporated by reference
in any filing under the Securities Act of1933, as amended, or the
Securities Exchange Act of 1934, as amended, regardless of any
general incorporation language in any such filing.
Item9.01 Financial Statements and Exhibits.
The following exhibit is furnished as part of this report:
(d) Exhibits.
ExhibitNo.
Description
99.1Analyst Day Presentation
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf bythe undersigned hereunto duly authorized.
LEMAITRE VASCULAR, INC.
Dated: December3, 2015By:
/s/ Joseph P. Pellegrino, Jr.
Name: Joseph P. Pellegrino, Jr.
Title: Chief Financial Officer
3
EXHIBIT INDEX
ExhibitNo.Description
99.1Analyst Day Presentation
4
EX-99.12d24041dex991.htmEX-99.1
EX-99.1
Exhibit 99.1
DISCLAIMERS Forward Looking Statements This presentation
contains certain forward looking statements that involve risks
anduncertainties. Actual results and events may differ
significantly from results and events discussed in forward looking
statements. Factors that might cause or contribute to such
differences include, but are not limited to, those discussed inRisk
Factors in our Annual Report on Form 10K and subsequent Quarterly
Reports on Form 10Q filed with the Securities and Exchange
Commission. We undertake no obligation to update publicly any
forward looking statements to reflect newinformation, events, or
circumstances after the date they were made. Non GAAP Financial
Measures This presentation contains non GAAP financial measures.
Non GAAP financial measures are not prepared in accordance with
generally accepted accountingprinciples and may not be comparable
to similar non GAAP financial measures used by other companies. The
most directly comparable financial measures calculated in
accordance with GAAP and a reconciliation of GAAP to non GAAP
financial measures areprovided at the end of this presentation.
Other Unless otherwise specified, all information contained herein
is provided as of September 30, 2015, except that all management
guidance is as of December 3, 2015 (unchanged from that given on
October27, 2015). Slide 2
AGENDA Time Speaker Topic 9:30 George LeMaitre Company Snapshot
9:45 Dr. Clem Darling Endovascular vs. Open Surgery 10:05 Peter
GebauerWorldwide Sales 10:25 Ryan Connelly Research and Development
10:45 Dave Roberts Acquisitions 11:05 JJ Pellegrino Financial
Perspectives 11:25 Dr. Alan Dardik Biologics, Today and Tomorrow
11:45 George LeMaitre Final Thoughts and Q&A 12:00 LunchSlide 3
George LeMaitre Chairman and Chief Executive Officer Joined
LeMaitre in 1992 Chairman of the Board since 2004 BA in History
from Stanford University MBA from the Stanford University Graduate
School of Business At LeMaitre: sales andGrew company from $11mm in
operating profit in 2015 $1mm in sales to projected $78mm
Spearheaded IPO in 2006 Slide 4
ANALYST DAY 2015 Leveraging the Business Model Leveraging
Leveraging Size Expertise Oper Leverage We aspire to achieve 10%
sales growthand 20% profit growth. Slide 5 COMPANY SNAPSHOT
Thumbnail Sales Office $78.0mm sales in 2015* $11.0mm operating
income in 2015* 14 peripheral vascular product lines 335 employees
85 direct sales reps Melbourne, Australia Sales Office &
MfgAcquisition and R&D strategy $23.6mm cash, no debt Dividend
payer Slide 6 *Management guidance, December 3, 2015
COMPANY SNAPSHOT LEMAITRES STRATEGY Focused Call Point: Niche
Markets Growth Platform Vascular Surgeon Sales
forceexpansionR&D introductions Acquisitions Slide 7 COMPANY
SNAPSHOT LMAT Is Right Sized for Call Point WHY THE VASCULAR
SURGEON Vascular surgeon founder 30yr history in the space Niche
specialty Owns the patient Can do both open & endo Slide
8Source: Survey of LMAT Sales Managers & Reps, January 2015
COMPANY SNAPSHOT We Play in Smaller Peripheral Vascular Markets
$4 Billion Peripheral Vascular Market Slide 9 Source: 2014
MillenniumPVD Reports, IMS Data & Management estimates COMPANY
SNAPSHOT Our Niche Markets 14 Product Lines $725mm Addressable
Market ~20% of Peripheral Vascular Market
COMPANY SNAPSHOT Our Core Products These products represented
~80% of our sales in Q3 2015. COMPANY SNAPSHOT Our Core Products
Slide 12These products represented ~80% of our sales in Q3
2015.
COMPANY SNAPSHOT We Aspire to Achieve 10% Sales Growth Slide 13
*Management guidance, December 3, 2015 COMPANY SNAPSHOT and
20%Operating Profit Growth Slide 14 *Management guidance, December
3, 2015
COMPANY SNAPSHOT Experienced Management Team Years at Name Title
LMAT George LeMaitre Chairman and CEO 23 Peter Gebauer
President,International 18 Ryan Connelly Vice President, R&D 13
Dave Roberts President 18 JJ Pellegrino CFO 10 Presenters Average
Tenure 16.4 Slide 15 R. Clement Darling III, MD, FACS Chief,
Division of Vascular Surgery Professor of SurgeryDirector, The
Institute for Vascular Health and Disease Albany Medical Center
President, The Vascular Group Slide 16
Peter Gebauer President, International Joined LeMaitre in 1997
16 years at IMPRA, Inc. (Bard) BS in Business from University of
NewHampshire At LeMaitre: in 2015 Grew International business from
$250k to projected $29mm Converted distributor to direct business
in 16 markets Slide 17 LEVERAGING SIZE Current Worldwide Sales
Reach: 85 Reps December 1, 2015 Rep Count:85 Worldwide Capacity:
125 150 Corporate/Field Offices
LEVERAGING SIZE Potential New Rep Locations Worldwide Capacity:
125 150 Corporate/Field Offices Recently Added: Export Mgr.
#2LEVERAGING SIZE Sales and Rep Growth Alignment Slide 20
*Management guidance, December 3, 2015
LEVERAGING SIZE Rep Tenure Contributing to Sales Growth Average
Tenure in Months Sales Per Rep Slide 21 *Based on 2015 management
salesguidance, December 3, 2015 LEVERAGING SIZE Proven Go Direct
Record 15 0 3 (Win Loss TBD) DISTRIBUTOR BUYOUT MULTIPLE SALES CAGR
YEAR COUNTRY SCORE SALES GROSS PROFIT SINCE DIRECT 1999 Germany N/A
N/A 26% W 2001 Belgium 1.3x 0.8x 25% W2001 Austria 0.5x 0.8x 18% W
2001 Netherlands 1.2x 1.6x 23% W 2002 UK 2.9x 2.4x 32% W 2004 Japan
0.3x 0.8x 17% W 2006 Sweden 0.7x 1.1x 13% W 2007 Canada N/A N/A 20%
W 2007 France N/A N/A 22% W 2008 Italy 1.5x 3.6x 12% W 2011 Spain
2.3x 5.1x 18% W2011 Denmark 0.9x 1.4x 11% W 2013 Switzerland 0.8x
1.3x 108% W 2014 Norway 2.1x 3.6x 151% W 2014 China N/A N/A N/A TBD
2014 Australia 1.0x 0.6x 258% W 2015 New Zealand N/A N/A N/A TBD
2016 Finland 0.6x 1.0x N/A TBD Median 1.0x 1.3x 22%
LEVERAGING SIZE >50% of Our Hospitals Purchase 2 LMAT
Products WW Direct Hospital Product Penetration (Ex Japan + Italy)
# of LMATProduct Lines Purchased Slide 23 LEVERAGING SIZE Surgeon
Training Has Ramped Since 2011
LEVERAGING SIZE Success with GPOs in Germany Slide 25 LEVERAGING
SIZE Burlington & Frankfurt Infrastructure Support Sales Slide
26
LEVERAGING SIZE Case Study: Finland Direct Direct as of January
1, 2016 18th go direct market One local sales rep Leverages Tru
InciseOUS acquisition customer base Slide 27 LEVERAGING SIZE EU
Warehouse Processing +25% Orders Each Year Orders Processed by EU
Warehouse Slide 28
LEVERAGING SIZE 35% of US Orders Are Placed through GHX Slide 29
LEVERAGING SIZE Case Study: China LMAT China LMAT China LMAT Base
TodayFuture 14 product Shanghai More lines office products
Go-direct Three product More expertise lines approvals Regulatory
approved More expertise Four salespeople Strong employees balance
sheet Slide 30
LEVERAGING SIZE Case Study: China Sales running at ~$1mm/year
CHINA FDA APPROVAL RUNWAY Product Timeframe VascuTape Q4 2015
Pruitt ShuntQ1 2016 Embo Catheters Q2 2016 REP HIRING RUNWAY City
Population Beijing (hired) 19 million Shanghai 22 million Guangzhou
11 million Tianjin 11 million Shenzhen 10 million Peter Gebauer
President, International Q&A until 10:25am ET Slide 32
Ryan Connelly Vice President, Research & Development Joined
LeMaitre in 2002 Head of R&D department since 2006 BS in
MechanicalEngineering, MS in Manufacturing Engineering from Boston
University At LeMaitre: Oversaw development of 15 accessory, next
generation or de novo product lines Coordinated transition of
biologics to LMAT Slide 33 11 WINS 5 LOSSES 1 TBDYEAR PRODUCT YEAR
PRODUCT YEAR PRODUCT 2001 1.8mm Valvulotome 2007 TT Delivery System
2013 AlboSure Polyester Patch 2002 Novasil Latex Free Embo 2008 TAA
Top Stent Catheter 2011 O T W Valvulotome Reddick Scoop Tip 2003
2011 The UnBalloonCholangiogram Catheter 2004 Flexcel Carotid Shunt
2013 MultiTASC 2004 InvisiGrip Vein Stripper SUCCESS METRICS 2004
Distal Perfusion Catheter 2004 5F Plus O T W Embo THREE TYPES OF
PROJECTS Sales CAGR Catheter Project costs 2007 Pruitt F3
CarotidShunt SKU Expansion Gross margin 2010 AnastoClip GC New IRR
2013 1.5mm Valvulotome 2014 HYDRO Valvulotome Next Generation Slide
34
LEVERAGING EXPERTISE Team Competencies Slide 35 LEVERAGING
EXPERTISE R&D Engineer Tenure Rising Slide 36
LEVERAGING EXPERTISE 14 Product Development Platforms PROJECT
CRITERIA Vascular surgeon call point Disposable/implantable Niche
marketsInvestment size Portfolio fit LEVERAGING EXPERTISE Diverse
Materials Expertise Slide 38
LEVERAGING EXPERTISE Application of Materials & Processing
Expertise Material/Process Expertise Expertise Developed
AppliedUltraviolet Light Catheters MultiTASC Bonding Hydrophilic
Coating TT Introducer HYDRO Valvulotome Laser Welding MultiTASC
AnastoClip Slide 39 LEVERAGING EXPERTISE Volumes Justify
Automation: Balloon Tying Balloon Catheter Units Slide 40
LEVERAGING EXPERTISE Case Study: HYDRO Valvulotome LEVERAGING
EXPERTISE Case Study: Building the Pruitt SmartShunt
FEATURESElectronically monitors blood flow Visual & audible
alarm signals no flow Targeting first-in-man H1 2016
LEVERAGING EXPERTISE Regulatory Approval Frequency Increasing
LEVERAGING EXPERTISE Regulatory Coverage Extending to China Slide
44
Ryan Connelly Vice President, Research & Development Q&A
until 10:45am ET David Roberts President Joined LeMaitre in 1997
JoinedLMAT Board of Directors in 2001 BA in Business Economics,
Brown University MBA from Stanford University Graduate School of
Business At LeMaitre: 17 Acquisitions in 17 years CFO during IPO in
2006 Slide 46
LEVERAGING EXPERTISE 17 Acquisitions in 17 years Slide 47 *Mix
through Q3 2015 applied to 2015 management sales guidance
LEVERAGINGEXPERTISE Acquisitions Record 9-4-4 9 WINS YEAR PRODUCT
SALES CAGR* 1998 VascuTape 14% Embolectomy 1999 9% Catheters
Carotid Shunt, 2001 8% Embo Catheters 2004 AnastoClip 9% 2007
LeverEdge 1% 2007 EndoRE 4% 2012 XenoSure** 53% Carotid Shunt,2013
N/A Embo Catheters*** 2013 TRIVEX 4% Wtd Avg Sales Multiple Paid
1.1x 4 LOSSES 4 TBD SALES SALES YEAR PRODUCT YEAR PRODUCT CAGR*
CAGR* 2003 Dialysis Grafts Closed 2010 LifeSpan 2% 2005 Stent
Grafts Divested 2014 Omniflow II N/A 2007 UnBalloonDivested 2014
Angioscope N/A 2007 AlboGraft ?1% 2015 Tru-Incise OUS N/A No loss
since 2007 Wtd Avg Sales Multiple Paid 3.0x Wtd Avg Sales Multiple
Paid 2.5x PROJECT CRITERIA SUCCESS METRICS Used by Vascular Surgeon
Sales CAGR RecurringRevenues Integration Cost Low Rivalry Markets
Gross Margin Accretive Accretion Short Learning Curve IRR Weighted
Average Sales Multiple of all 17 acquisitions: 1.6x *Calculated
from year of acquisition through 2014 Slide 48 **Sales CAGR
calculatedfrom sales pre-distribution by LMATs sales force (2008)
***Ceased supply of product to European competitor; significant
uptake of LMAT products as a result
LEVERAGING EXPERTISE Proprietary Deal Sourcing and Pipeline
Private Equity MD Innovation Succession Plan Orphan Product
Carve-OutLEVERAGING EXPERTISE Disease State Expertise Dialysis
Access AnastoClip Embolectomy Catheter PTFE Graft Vein TRIVEX
Carotid (arterial) Carotid Shunt XenoSure Abdominal (arterial)
Dacron Graft Peripheral (arterial) Valvulotome EndoRE Omniflow
IISlide 50
LEVERAGING EXPERTISE Disease State Expertise Dialysis Access
AnastoClip Embolectomy Catheter PTFE Graft Biologic Graft Chronic
DialysisCatheter Vein TRIVEX Vena Cava Filter Ablation Catheter
Slide 51 Carotid (arterial) Carotid Shunt XenoSure Decellularized
Patch Vascular Sealant Abdominal (arterial) Dacron Graft Pledget
Adhesive Barrier Steerable Catheter Peripheral
(arterial)Valvulotome EndoRE Omniflow II Mechanical Thrombectomy
Atraumatic Clips & Clamps LEVERAGING EXPERTISE Domain
Expertise: Open & Endo Slide 52 Source: JVasc Surg V50, Iss 1,
Pgs 54-60 ; Mgmt Estimates (2006-2012); Millennium RG
(2013-2023)
LEVERAGING EXPERTISE Domain Expertise: Call Point Dynamics US
Peripheral Interventions: 1998 2012 Slide 53 Source: J Vasc
Surg2009;50:946 952; Mgmt Estimates (2006-2011); advisory.com
(2012); escardio.org; acc.org LEVERAGING EXPERTISE Case Study:
Omniflow II Biosynthetic Graft Result: Sales 71%* Units 27%* Slide
54 *12 months ended September 30, 2015 vs. pre-acquisition
LEVERAGING EXPERTISE Acquisition Strateg Slide 55 LEVERAGING
EXPERTISE Generates Cross Selling Opportunities Slide 56
LEVERAGING EXPERTISE 17 Acquisitions Integrated in 17 Years
LEVERAGING EXPERTISE Acquisitions Core to LMAT Strategy
David Roberts President Q&A until 11:05am ET Slide 59 JJ
Pellegrino Chief Financial Officer Joined LeMaitre in 2005 Chief
FinancialOfficer since 2007 B.A. in Economics, Harvard College and
M.B.A. from Harvard Business School At LeMaitre: Manages Finance,
IT and HR functions worldwide Has overseen over $15mm in
cost-cutting initiatives Slide 60
FINANCIALS 2015 Sales (+10% reported, +13% organic growth) Slide
61 *Management guidance, December 3, 2015 FINANCIALS Niche
MarketsAllow for Price Increases Worldwide Price Hike* Slide 62
*Approximate, in LMAT Direct Territories
FINANCIALS Operating Profit A New Chapter Slide 63 *Management
guidance, December 3, 2015 FINANCIALS LMAT ComparativelyProfitable
Slide 64 *Q3 2015
FINANCIALS XenoSure Contributing to Gross Margin Slide 65
*Management guidance, December 3, 2015 FINANCIALS Case Study:
XenoSureManufacturing Efficiencies
FINANCIALS SG&A Leverage Slide 67 *2015 Sales based on
management guidance, December 3, 2015; expenses are annualized
based on Oct.2015. FINANCIALS SG&A Compares Favorably to Peers
Slide 68 *Q3 2015
FINANCIALS EBITDA Funds Dividends & Acquisitions Slide 69
*Actual through September 30, 2015 and annualized for Q4 2015 **As
ofSeptember 30, 2015 FINANCIALS A Balanced Approach to Capital
Allocation Sales Gross Profit Sales Operating Expense R&D
Channel Operating Profit Acquisitions Dividends Slide 70
FINANCIALS Potential Sources of Acquisition Funding Acquisition
Size Funding Source(s) $25mmCash + Debt + Equity Slide 71
FINANCIALS 2015 Guidance Remains Unchanged 2015 FY Sales = $78.0mm
10% reported growth 13% organic growth 2015 FY Operating Income =
$11.0mm 73% growth 14% operating margin We aspire to achieve 10%
sales growth and 20%profit growth. Slide 72
JJ Pellegrino Chief Financial Officer Q&A until 11:25am ET
Slide 73 Alan Dardik, MD/PhD, FACS, FAHA Surgeon Chief, Vascular
ServiceVA Connecticut Healthcare Systems Scientist Principal
Investigator, Dardik Laboratory Yale University Professor Professor
of Surgery Yale University Slide 74
FINAL THOUGHTS Leveraging the Business Model We aspire to
achieve 10% sales growth and 20% profit growth. Slide 75 FINAL
THOUGHTS 2016Direction
FINAL THOUGHTS 2016 Direction SmartShunt Long A?Clip New
XenoSure Sizes Addl. OmniflowSKUs Finland Poland? Czech Republic?
Portugal? 5More Sales Reps Avg. 1/Year Since 1998 Slide 77 FINAL
THOUGHTS 2020 Direction Slide 78
FINAL THOUGHTS LMAT Analyst Day Closing Prices Slide 79
GAAP to Non-GAAP Financial Measures Reconciliation
Reconciliation between GAAP and Non-GAAP
EBITDA: 2009 2010 2011 2012 20132014 2015F
Net income (loss) as reported $ 1,598 $ 6,013 $ 2,143 2,571 3,202
3,915 7,100
Interest (12) (26) (11) (77) 8 (16) (10)
Taxes 617 (1,988) 1,609 1,422 1,126 2,405 4,000
Depreciation and amortization 1,419 1,376 2,037 2,234 2,793 3,334
3,400
EBITDA $ 3,622 $ 5,375 $ 5,778 $ 6,150 $ 7,129 $ 9,638 $
14,490
Reconciliation between GAAP and Non-GAAP sales growth:
For the year endingDecember 31, 2015
Net sales per guidance $ 77,967
Impact of currency exchangerate fluctuations 5,410
Net impact of acquisitions and divestitures excluding currency
(3,401)
Adjusted net sales $ 79,976
For the year ending December 31, 2014
Net sales as reported $ 71,097
Net impact of divestitures excluding currency (76)
Adjusted net sales $ 71,021
Adjusted net sales increase for the year ending December 31, 2015$
8,955 13%
Slide 80
Amounts are in thousands and are unaudited
Management guidance is as of December 3, 2015
GAAP to Non-GAAP Financial Measures Reconciliation
Reconciliation between GAAP and Non-GAAP operating income
growth:
For theyear ending December 31, 2015
Operating income per guidance $ 11,012
Impactof currency exchange rate fluctuations 2,568
Adjusted operating income $ 13,580
For the year ending December 31, 2014
Operating income as reported $ 6,320
Operating income as reported $ 6,320
Adjusted operating income increase forthe year ending December 31,
2015 $ 7,260 115%
Slide 81
Amounts are inthousands and are unaudited
Management guidance is as of December 3, 2015
GRAPHIC3g2404102.jpgGRAPHIC
begin 644 g2404102.jpgM_]C_X 02D9)1@ ! 0$!+ $L
#_X@Q824-#7U!23T9)3$4 0$ Q(3&ENM;P(0 !M;G1R4D="(%A96B 'S@ " D
!@ Q !A8W-P35-&5
!)14,@ML![\'T@?EM!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".0F/":0)MN@G/">4)^PH1"B@2!Q(F$D429!*$$J,2PQ+C$P,3M(Q-#$V,[email protected]$\43Y10&%"!6;%;T5X!8#M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$
891B*&*\8U1CZ&2
9M11EK&9$9MQG=&@0:*AI1&GZ1\3'SX?:1^4'[\?ZB
5($$@M;""8(,0@\"$K-% 6(_L\7EE/+CV,W0,6"Q1!
">IP!U/>I?L\7EB/RX_+!R$VC
YST^M244"LB"6QMKB>*:>WM@DFMR3%(\8+1YZ[3U'X5*B+&H6-551T"C
%.HH&5;K3+.]FBEO;2VN)8#F)YM85=D^A(XJP(T#EPJ[R,%LF:=10%B,6\2A0(HP$.5PH^4^HJ&ZTJRO9XIKMVSM;B:'_
%4DL*NR?0D9%6J*!60WRUW[]J[\8W8YQZ9I)88YUVSHDBYSAU!%M/HH&0I96\1!B@A0@Y!6,#!]:>8D+%BB%F7:25Y(]/I3Z*
L5;+2[/3%==-M+M:T60Y&O\ TYP5[]7@/[:?_),?#/\
V4+PU_Z//#MV?#_P"*D/B!H]/UW9;ZDW$QM?!7Q:UQ#)H5\^7@4R6A8\E/XD_
\CV)]*]5KY8T#5Y-
UJSU"#.ZVE#,/5>CM#\1D5]1P3)#0>A]J3ZMN4445\\>V%%%% !1110
4444 %%%% 'BW[,/\ Q[_%+_LIM^N_^C4KVFO%OV8?^/?XI?]E/UW_T:E>TT
%%%% !1110 4444 %%%% !1110M 4444 %%%% !1110 4444 %%%% !1110 4444
%%%% !1110 4444 %%%% !M7@/[:?\ R3'PS_V4+PU_Z9$9CN95X5B>6
XY.*WZ0@M,"&
(/4&KA)1DFU=(BI%R@TG9L\PL?BUPVRL]M>";R)99)E'(4;_N*&'&WGK7FGQVX\=G/_
#Y1M?S:MOQT?V@$\,W/_ A\?PY;4RR>5]E,_F
;AN*^?^[Z9^][XYQ7(_%(ZH=7MTL^*A;#6CHUK_:
MO]4)]I\S9_L[LXK\R\6J$(Y!&JOP1\32:'\2=.N%E40ZQ>26=R"HW.735LFM42L)"0,[CT/85X'XXUZ*3XN:6()'5=/,EM?RP#>0LP+XQW*[0>,XQ7T$;ZQ[M_P!(^!I2T_PZ_P"?X'LWP_OB]I>:=(C1MI(H+Z[BNY)#!+;21X(DM\-M8$<
'B7QGJ1@BDMTF6V)GMS(L5K)$3$)(F,@D9BHWC>K1$;E&FW%QYP4K833;'"IMC8$KM^9G_>'*MLQWIVF>*O&MY#M#%_9R+.Z0I)+&8));:\8AK>,;FMI>K(?\
9[@^E>CB*7UB'MJ:U^TOU7KU\SIJP]HNM>&_7_,P:*OZAX;U;28_,U+3[NWC/\O%0?\*TBT^.
SZC8EBJ6R^?8964"5G2(_/EE.\@M@DDD
YXPJM'SV_X)I2>'AI=G)B\MO)$2/E8N-Q/)Y^E?/L>GSP^(K6\NK;9]I6:XLRC'=-)
P9QGL3MD&1ZBO:?&M/BNXMM(FB;,MS\1?\ 76+_
-$I7N'COX4?%G7/M#5S9^'?B]);WLK)MHKH]M6\:7%A:Q7VMSSV/AL0.MTL-OYK0SL0$9\#=LY
..G4\5R.ILRS>2_+1LQ.>QM.*[,\14HHHKYH\@*^V/V=_\ DD&@_2;_
-'/M7Q/7VQ^SO_R2#0?I-_Z.>OH^&/\
>Y?X7^:/7R7^._3]4S9U(Y]Z[N\U8&Q6)N2@XYJ+P_\ ![QG
J&?PMK2%>@U'D+:M/#XD875RENN-
NDVELX/S(,].@R?0'FMMWXI^)DT/X=ZC?Q%LW$
2'*E6RX]#R#C/!JH585':#NSHPF,PV*FX4:BDU:]MG>U]CRWQ(-1^(0UKR;EK2&*UDGO)HE^=44';#N_NY4C
Z[6)ZBI/A;HZ^+_BM)+J46/[(\/QJL"*3MWK\L2_@
S_4BN,T?XJ27OA6^\,:#I)@U769!!#U:7D?&3_G]^&?_@#??_'::-*^M,)'_
",7P^_\$5U_\D4?V5\8?^AB^'W_ ((KK_Y(KW93BVW>G]S_
,CSHPDDMERU?O7^8[R/C)_S^_#/_ , ;[_X[1Y'QD_Y_?AG_ . -]_\
':JZE;_=.MNKMO$'P_1@>HXMZUR7Q'M([CXWZ-!?L[PWNGND:X/R$I(O'KDX_&O5/
6D7&@>#='T[4%1;FTMM$254Y"MCI[X]:XSXR>'[R\U'1-5L@
MB7B5UQOCE=EV'GJ.",>N/6J;LM":#M7M?6_P")N?"2[@_X1*+2X9A+^B_K^F?4MNH>*I=>L;*YWNUM)
LEHF[B ,
Q^HR37SS\?OVEK#X5VKZ5H0BOO$H%:OQY^,UC\,=&L?#/A^YMAXAGLUB1I6S'9H%P97[X&"0.I-?
KP7M7B#7;BXO[B6[EGE+S7,I):4YZG-?+4@R>*]C*LZKY=_JOA?YY?A_D?FU_PS#\4_^A.OO_
JW_\ CE'_ S#M\4_^A.OO_
JW_P#CE?I/)3VL4N6^U^MN[?8]++LKI8'F]FV^:V_DM+17SBWQ?\8>%+^>ZU*]@\16&GW'B,W=K)%%9M]GTUH]K(ZHZ2YEL;5IXVW+(8QD'KG\Z\DC_:)O+_6;ZPTGPE,ZQ:ZNCVMS))=1L+6=KFTA-H(!*X7:'SN)*@LM>PR15;]J1H+CQ#H,4%Q:3S65I*DT2#[A*28W#J.&%>T^%)+F;P+87"ZIHNJ7M$"-NN=/MO*B?Y\;0!T(&
1ZYK@KX/#U,6I2BKI)_.[W/J*.9XW#Y$HTYM*H$;.-OM7O?BKQAS7%?$OPMK/X6\(^%=6M+=);O2I"EY&^2',_+J?8L63_@0KT$KNU^Y\W2K>R:DU?5?G&>:V::66YE\D+!&Z+M7"DELN"!MP!CW%$?#6C7EGH-\MF]Q>ZV]N\KF&.4D(L#X&)0.O8TR]MN?'NI-"VH^!O!MTUL_F0F;Q
[F-O[RYM>#[BNZ&%G%KGMM_,NJTZG!4Q2);5E1D34O,(#>6VXA1'D[C\W3G%=3X+UMNZU[29+B_1=T=P\22J@19E
'S !F&,DCACG;^%;OEJ,85?EZ\.Y.%3&MY>6) SG
SFM=8U0DHJJ3U(&,TK*KC#@,/0C-
'G=Y\0-1MH[N4S:,GD([212M;OW&R2-02V[YA('8IP.@//-='HFOSZCXDU:Q=[>:VM$C>"6$#^(L"I(9NF%ZMA2&O\
TYP4 CWZBBB@M HHHH **** "BBB@ HHHH **** "BBB@
KXO\;?M5?$C0?&6NZ;IEIIK6>GZMC/;V[-I4K$HCE5)(;G@=:^T**[\!BZ.'DW5I*=^_3\&,PU6LDJ=1PMV_X=M'S7\%OCGXQ^(.D:[+XK6UL!8WEC"+J"P:+[-#*SB60AR0O(]:FL[.#3[6*MVL88X+>!
D44:[511T %
'G\OQ-U*"RMYI=,M1+.;IXXC,X,ZPS"(11_+S,_M+!>@'KU&/9^./$MF8#=RVCO=:A^_DG5A##";YH,*
H*D*HY)(YSWKUW _*C%M #969(G:-#(RJ2J
@;CZ*WM+>UEANE*HQ:266&ZCBS&V"I4JMY;'/&>>,UZP
!THP...G2H$>7:C\7=2T^TE=]'MS-(Q^R+Y[X(\V=,/\O4^1MGC@!\[email protected]\:ZEH.H>'[Z-EETG^SY;K5H+6(3^8N845HW
S\K2[N.JYKM-M5T6QUR&.+5;=)TB?S(\D@HV",@C!'!(^A(JU;V\5I!'!:QI##"@2.-%"JB@8M
'0 4 >3Z3\4]7TN2WT_P 0P)?:E+>W23!4\KRE!F,87
PP7RMI(R>A)Y&9MM72%OIRMR+[S6-=FLKVQB@A87;6\D_4444
%%9^OZPGA_1+[4IXIIX[&!IFCA7+N%&HKH* "MBBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **M*R-=\20:! _MI_\
),?#/_90O#7_
*:EJ-YY*6MT=FURL,@M4M_,$2A3'M8!97!WAL]>O-;6K>"8]2\(1^'K6^N-.M5B6)Y+:"$M,Z
!6;%;T5X!8#M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$
891B*&*\8U1CZ&2
9M11EK&9$9MQG=&@0:*AI1&GZ1\3'SX?:1^4'[\?ZB
5($$@M;""8(,0@\"$*-)%K=6]ZJ2>9#MDHHF4;4D!*\9(.1BH);SXBVOB'X9QCXB7DA^*ME,NI(^F0>5I92V6X#V2[(=%MFM+75M'N$CF:WM;!:&175DD0D!L,O!&1BIISBDD_/]#7$4:DI.4/+\&[_F>;Z?X^\0#X23K\2MM?\3>$;T>)I-+TK4AH2C5M;M\C>\M[G:4.W]WY?E[69?+V;?$FN:SH?BG2_%VIOK5WX1\4WNC1:E-$L?#S2[[QEX>\33O>?VCX9LKFSLE64",QSA
^]SJ_\ A;7CC_H./\
H\/3ZG)(=/M]2EC#W$5A*\D*$\@*S@M,>,W?[2'Q(N)[V_BLW\2W3'R[N0!$W]E!Q]
*OZ+\"KK4H#=*MX+1DR$N]4N#,M>."=C!5^G/UK&MC8X?64K7.[#Y=6Q&D(W/T8/[&WPF*E3X!\
X/4?V*/\*],MM_!J66D065I76AW-S"EUJT)@'F,IUM"5P5SC*G=SCCCWK]>/V5HFB_9K^&?9[".\C6T=D!\PI(!M(&7&/MNFK/@7XZ>*?'.H^'[&+PMI.GR:S9%_S\M6O\
W_7_ !H =13?,B_Y^+7_ +_K_C1YD7_/Q:_]_P!?\: '44WS(O\
GXM?M^_Z_XT>9%_S\6O\ W_7_ !H =13?,B_Y^+7_ +_K_C1YD7_/Q:_]_P!?\:
'M5)-]R#_KG_4U#YD7_/Q:_P#?]?\ &I9GC$_Q2_[*?KO_ *-2O::M"BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *M*** "BBB@
HHHH **** "BBB@
KP']M/_DF/AG_LH7AK_P!._5X#^VG_RM3'PS_P!E"\-?^G."@$>_4444
>9?$NO)KTKXKZ):>))[G3=5$YM+NMV1)1!":TFT2*2.-W:$RMSP'[05#20J%R58AC(@
SD5L2_'B+2=9U>XUOR!X@HP/0444 &!MZ"C
]!110!^=WQ3^*/Q)L_C9XRTW2/&OB6RT^VUN>&SM(+QECBC#855'8"LSMQU\;?''@&\-A'XK^(OB.>!%%[%?7'P.B^S_
0\*Q@$;(V XQW-=6%GM*I2C.74\K-#?$UK-IT[.P,4$V]U.T'#
.CIM@@C$GTKSE3:I\/?'.IG0/%VC7CQWQOTQM;W,I^;,25/*4;EQUYK$_X1[4O^?*;]/\:[G5P#>@KNIUI**1SRBKG)_\
"/:E_P
^4WZ?XT?\(]J7_/E-^G^-=9@>M@HP/057MY"Y4@HP/04>WD'*CD_M^$>U+_GRF_3_
!H_X1[4O^?*;]/\:ZS
]!1@>@H]O(.5')_\(]J7_/E-^G^-M'_"/:E_SY3?I_C768'H*,#T%'MY!RHY/_A'M2_Y\IOT_QH_X1[4O^?*;]/\M&NLP/048'H*/;R#E1R?_
CVI?\
/E-^G^-'_"/:E_SY3?I_C768'H*,#T%'MMY!RH^,/''_!,_P;X^\=^(/%>L7WC2'4/$E_)>W45O=0")'$'((_4U]DX'H*,#T%1S*][(TCM4E'9L^*==_X)B>"O$%W+U+_GRF_3_&N8TC]I+P7XAM89?#W]LZK+U+_GRF_3_
!H_X1[4O^?*M;]/\:YJ?X]:5IOC/Q/I6LVC6^E>'K31MF-1)&N?*5"V]F?
4(3F@#[6T[Q7=9%4CJ"5) -.AU6RN+QK2WO+66Z2-96@296SKQ6%\M+_
V@^#=/_8^\3^&K&*S\1^)Y/(UC5@Y:YU&*;1YI'CFD)RZ;HTVJ>$"@+@4M
?>DDB0QM),RI&BEF9C@*!U)/I7/Z[X\T70O!>K>*3>VU[I.CV4]W--:3)*&M6)"[*I!P6P,
9ZFO&_VV)H8OA]X37Q-)-#X%F\:Z9'XU='9(_P"RB[;Q,5Y$M!E\D/VV]>,UXWJFA>
=4\7?'*T^"MGX?O/AQ'\*7EUN'2(HY-)77(S-);M'LM'E>>L W,4Y&$)Y
H"Q]/_"+XG:[\0/ABOC'Q!H&GV(O[%=1TW3M*U7[=+);OM")4CD)1%6?!"E02N2/FJ73OCOX9U'X$CXL*]S#X9&AOJ\BR(!/&B(2\17./-M#*4VY^\,9K/_
&6?#6C^&_V?_ /_ CFF6&F#4O#FG7EW]DMUB^T3O:Q;Y7VMCYG;
RQY-?.MUI4MK\3]4_9N6.4:3KWCB+Q="IC/E#PXV;VZA!Z!?MT1@QZ3M4
?86@^--,UNUTOS)X=/U+5+**Z72;N>-;N$.@?:\88GN\1QQ/8D[B85!2=H]J$;G(')H
^$O$MG[-G@+5?VROA[\.-=T%M5\$^&_A*Z6VGW4KF*8PWA6/SBN/,/[QGP>-V&QP*M\3\=+\*+&P_:&TK]H329+CXV7GB&]C\(K-8SRWDMML5=,&GL
=J+@9VD&[&_P#&5S\)!JFJRWD1?S==M51()Y3T,J&-!D_W>]>._!C0K76GM\
VGBCQW\-O!7Q(T?QM'=WT-SX:O%\63WYNV$D4\X;]ZDH;&=NS:5R1@U^N9MC0N'*J7
P&QR!]:@.FVAO/M9M;8W8&//\I?,QZ;L9H"Y^=?@"_\
#/P\_;*6MQ\&OX2^*,OC/QKJ,]X[Z/)#XF\'7)$BS.\S+S:J"RC.
5Y7KD\Y\#+NS\#_$M?7/!_P #9/"'Q-U'6=
\0WVD>+]/TB2T\0^'KIHG98=1D8?-OE"HH8AL@<
8M%?IS'86T5U)?M'VZW'PM:@8RX!=(TC3-5U7QGX5LM,UH9TV\N-8@CAO!GM'[IRV'Y]":TO$7CGPYX0TF/5?%FOZ-HVF3%1%>7]_';PR%AD;7
O %UX/M-/\)3^(/ TFMZ;%
-QN;6V$;*MM+YKNMY[L",8XS2L=$\&_##Q'\![[XZW=Y\0/@[IW@K4;'1]:O_#ER;.+4#=N5:6T=M6=/W)6-"ZG("DW#9Y^;J
:^V?#GCC0=;\1^(?"^@7&_4O!IM8=M3MA"R+;>=%YD*AB,-E.?E)QWH
\D^(?[1OCGP!XXTCPZWP@N]0'B?5I].\/7M_M^TTNZUJ=["PU
S"9YX+?=L5G"P&
3GE=)_9'MMO&?B?XA^(OBK>>([&[\8^(YS-8Z+XDGMK?4='CCCBM8+I(V
8%(V) PW[PJ3MCB@#OOV5/'&O?$?X >$/$7C>*?\+0^-'_1#['_PO[;_
.,4?\+0^-'_ $0^Q_\M"_MO_C% 'L6HVDE]8S0074]E)(N$N(-N^,^HW
C\P:Y.T^%6F6R_/?E4>U>2?LW^$M_$WA?PYXJG^(6DV^AZIXE\8:EK2V$%^MX+>*X9613*H
8C!SP*];H **** "MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHMH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **M**
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHMH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@M HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "MBBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **M** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHMH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@M HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "MBBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **M** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHMH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHMH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **M**
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHMH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@M HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "MBBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **M** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHMH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@3 HHHH **** "BBB@ HHHH
__V0$!
end
GRAPHIC10g2404109.jpgGRAPHIC
begin 644 g2404109.jpgM_]C_X 02D9)1@ ! 0$!+ $L
#_X@Q824-#7U!23T9)3$4 0$ Q(3&ENM;P(0 !M;G1R4D="(%A96B 'S@ " D
!@ Q !A8W-P35-&5
!)14,@ML![\'T@?EM!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".0F/":0)MN@G/">4)^PH1"B@2!Q(F$D429!*$$J,2PQ+C$P,3M(Q-#$V,[email protected]$\43Y10&%"!6;%;T5X!8#M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$
891B*&*\8U1CZ&2
9M11EK&9$9MQG=&@0:*AI1&GZ1\3'SX?:1^4'[\?ZB
5($$@M;""8(,0@\"$#VH,_M4YM/
>@ZO=(\FC^'OM%VDZEK052P%E%.-[L.ZH2CGT"D]J]FKE_%?Q!\*>&9SIOB_5M.LY;F#1@Y!PPYZX-:T5)S7*K^AAB7#V34Y))]679?%VAS0V20ZSIW^1B^"/
^C^+OVDOBIJ/B6W.I2^'-0TB728KB0M%93-9HQFC3M.!(=B#=UP,=SGB/!7AU=-^#/Q6\?:'!+>^.=+U/Q/'H^H2,TLM@B33
1P9/RM+DL^!U8Y.]>M.J[KXNKWV:T]#S?6M T/X?\
Q3\6:'\)XK?3M$N_AIJ%YKVF:?*1:V]PK;;6M;8#MCE93,.,$AO^!M&\.?L1C7+&WWZWXAT30Y=5U.=S)SAV1F?\(SH__0)TW_P$3_"E_P"$:T?_
*!6MF_\ @(G^%:5%'M)]P]G#LC,_X1G1_P#H%:;_ .
B?X4O_",Z/_T"M-_\!$_PMK2HH]I/N'LX=D9O_ C.C_\ 0*TW_P !$_PI/^$9T?\
Z!.F_P#@(G^%:=%'MM)]P]G#LC,_X1G1_^@3IO_@(G^%'_",Z/_T"=-_\!$_PK3HH]I/NP]G#LBE:MZ)IUC,);*PLK>4
@/%;JC ?4"KM%%2VWJRE%+9'BW[,/_'O\4O\
LI^N_P#HMU*]IKQ;]F'_CW^*7_93]=_\ 1J5[32&%%%% !1110 4444 %%%%
!1110 44M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
!7@/M[:?_
"3'PS_V4+PU_P"G."O?J\!_;3_Y)CX9_P"RA>&O_3G!0"/?J\NTX*WBM7QJLA;!UR,G!Q_RYVU>HUYAI>/\
A)?&Q/ &MIR?^O.VK'%?[M4^7YHS?\6GMZO\
)FM/$I,]/Y5\/FDXSQM647=.3/K,!&4;G[1ND2+9O\
+V_>(S]TM]*^>O^&6OB?_ -"R?_
V'_XJOM\BQV%IY?3C.I%/71M=V?)YMA,1/&3E:TMV3[(^G?V,?\
DBT?_85N?YK7NU>0?LS>$M9^'GPQ32/%VGS66H"_GE,2D2?(MQE21VKUJ&X69F4*ZL@!(=2.#G'\C7Q&:3C/&U91=TVSZO+XRCA:W$8B,BM';-APNW>
3CE=PW#MSZ'$UM[X-MK[5)]0DO=12XF\O84E7$!3[NS*G'5LCD',Q9(XFQ:3M9);6[2.JLSL\C;F=F8LS$^I8D_C5N@#)U?Q-9Z'/''J(N4$JGRY%@9D=@"=@M(_C(4X'M45GXOT^^D$T;)*A1D=6*LI![@@MBK84*20
"W4@=:HZ'H\6@Z7!8VTLTT5N,(TQ!8C/@
'M5^@M#-U;Q!::))"-1\Z..;/[\1$QH0,X9AT)P?RJK8^,=/O[FWMT%W%DWIM;N.\\]ES
B6[-]H.5!$>/O$%ESZ9]MC5:3Q]I$=I+8+:]U"%)+6*V\L-&RA(R2.&0Y)+,23MG.X^V
"S8>*[+4=>N-'A6Y6]M;6.YD$D)50C],-T)]16QM
).!DC!-5].T^'M2K&WM+-2L-M$L48)R0JC !)ZU9H
A>T@EN(YY(8GGA!$)P4:/)*A>5M^9_?8X9T,4ZO-&K:/;E7YGGX^+T,-MM"EU;;K]H3+*EOF1(PLH5E!_B.TD@KD$BMWPQX_M?$]Q;PPVMS:MAV0K890M*E=]M^;]+'
6WQ?LAIQN=1LKN%V:+:K/':7:CX?&E>(/%?A+7[[6M=6L'N3:P7SW_
)OVA(92#L*&;Y2PP=O.,XKZ2HIJO)=/ZM83P-/!R:5INE6M\9?)N5%P"T[A=N3YJ9*Y&..2"3],T5?UB=K?UTM_P
C#ZA2O?7_ (>_EYOR/F?Q1\
-5M=?\->(E\)>'?'GV;PE9Z'JNC7]]]E:M&6WY6>WE92I&6=64@9&"/2M[4?A[J2_#&ST2+X/>![S3[N\N)M0\,QZR(A;LMQ'E31SF':9>N\@*1QM8U[U12]O)VOT]?\RE@J:O;KZ?JO^
0@WK07@O@8QM^?=EOZ]>IY'XP\*^+=M.^.^A^-?".DV&MZ=-H#:'J,,VHBTDLPURLHG&582
#_P 4O^RGZ[_Z-2O::\6_9A_X]_BE_P!E/UW_ -&I7M-M!1110 4444 %%%%
!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %M%%% !1110 4444 %%%%
!1110 5X#^VG_P DQ\,_]E"\-?\ IS@KWZO ?VT_M^28^&?\ LH7AK_TYP4
CWZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HMHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBMB@ HHHH **** "BBB@ HHHH ****
"BBB@#Q;]F'_CW^*7_93]=_]&I7M->+M?LP_\>_Q2_[*?KO_ *-2O::
"BBB@ HHHH **** "BBB@ HHHH **** "BBBM@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@
KP']M/_DF/MAG_LH7AK_P!._5X#^VG_R3'PS_P!E"\-?^G."@$>_4444 %%%%
!1110M5Y?XG\=:A8>/HUTTWATK3I(M/NP;;-HUQH5$UM"Z.MKQ1LLC;G4H"&/')]3P/RH
\JNOC3>S:7!=Z1IWDI+Y?E[Q'G
;9\M;EK8VUA$8K&W@MXR22D480$GJDCY4[XQ
V(SF,MA$M/U:[M\R:+6EM8XVU2_%R(Y#&[R3LS,@16PBK&7
!/;H>\\'>*=:\2:K(M];Z;9V5OMI]K-+'&QED,TR%B%ZN&NK=7MTOKTW$4NZ\,;3_-L$2QJ5#)N
^=.1C-M;DWQ!+1IDT"&5K
71M3.9)+\_:'BV6Y1RNYE0$#+X+8YY->LF&,KM*(5(M(P5&,'J*J)HME'J/VY+>-;KR%@#@?=12Q4
=!@NW3UH O4444 %%%% !1110M 4444 >+?LP_\>_Q2_[*?KO_
*-2O::\6_9A_P"/?XI?]E/UW_T:E>TT %%%M% !1110 4444 %%%% !1110 4444
%%%% !1110 4444 %%%% !1110 4444M %%%% !1110 4444 %%%%
!7@/[:?_),?#/_ &4+PU_ZUTD0F_=XUGD$:N(F90Q( W$ A020,G YH
Q/"&GZI9WEX^K+M7>_\]K;_ORW_P 51Y=[_P ]K;_ORW_Q56Z* *GEWO\
SVMOM^_+?_%4>7>_\]K;_ +\M_P#%5;HH J>7>_\
/:V_[\M_\51Y=[_SVMO^_+?_M !56Z* *GEWO_/:V_P"_+?\ Q5'EWO\
SVMO^_+?_%5;HH J>7>_\]K;_ORWM_P 51Y=[_P
]K;_ORW_Q56ZAO+D6=G/M(\3_
/"'!-/U&U;QG:7ES:^9L98$MMB=_F$'JVTK%"%WY?R=H/(A*^7YF>072SO#
NZ3R8C(MP4=3@[email protected]["L>7Q_HL,KQO-,'+WJCC\[%SPS/>SZ=(=72\6=+N=4-U$L;M%YC>6=J]3UX'O46GZE!JD4DEF7*Q3/"^^,H0Z'##!YZU-G$QS_US(MUX8(U>+8%X1@>=Q)&""
,'/45I33_*O)-&$>"#GYE&M1QRBX^;^-LG
![>M*ZFFN:5_GE2W!ACEG+>>D*M]F?:[.Y0%6Q@J'!4GH#Q7MTI24-(M7^7H>-5C%SUG;ROZDOAB>]GTZ0ZNEXLZW+S#Y;87C&S;6DV?,?:M2&\O@@9P>:BT_4H-4ADELRY6*9X7WQE"'0X88//6ILXF)/\
@.:UHY$FC22)@ZM2*&5AT(/(-^B6>.7RA'+\AD;)7Y,_>&0M1QZ&MFKK.5U>-B**C9VES!3)_P#5'\/YT^F3_P"J/X?SK![&ZW)#UI*4]:2@M0R?=Y$GE$A]AVE1DYQQ@=ZX^RO/$$&C:4EY#J\MXE\@N95MD8SP$L"SJ3\FM,E1R/EY.:[-CM4DYP!G@9-9,GBG38M+L]1DFD6UU"5(KLYN\F[6\C2"M%*]_,*8G^LD_WMA_(4^F)_K)/]X?R%0RUU'T444".,\:77B-+FYA\,)J.'LX_+ECMD:.*3S1NPM3\Q8IG(YQVJSHDOB2/6(EUF*6>QG0L9"(T\AB@.&
Z@'Y1CJ2QZ8K7U'Q)8:M3+^#Z5U\\O9V]FK=[?J,=)LM0:QN;EENT+
Q")B5Y./G1_,&.> 9"7('5N34WBV6]AT"MZ;18[Z2].U819!3(&)
W?,"-HZGC)
('-+6E34_>A=][>IUNF:3#I"3I:O>0SS&0[V.6P3T'M5G&9B#W0?S-9'A-M2;3IO[=%SYJW4@A:Y55=HN"N0,M>I'([>F*U7SO?:Q(.WD<
,>X-=WL:G+_ !%Z7.%UMJ?/_
WZV_KN>AT4M)7"=PR3[\7^\?Y4^F2??B_WC_*GT#?0Q[SPCI-_JR:GM=VI>]26&59/,8?-$&"'
..-Y^N!GH*V*XW5G\6+XF$6F*[:0\R+YH6/Y$D"[MFYY_=F-_KYZ]9M3A6&Z@AAU!KU3X^>-M41-,^'OPYG,7C7QQOAAN%Y_MLFQ'%Q?/Z;5.U/5V&.AK.E_9=L)?AM+X8E\0ZEVX>M?&EAX&U;Q#\!MM$\6ZY-H&?B-?:E;>#KZ;4/[+M*+8PNT\.HS)#&DA.1_XX\@KZ)LO@-K_
(5\0Z9J=]0#@7$/0'W,97'^X:^5/,:OUL^-GPIL?C+\/-1\-ZDX@EFMEL;K&3;7"?&Z@AAU!KU3X^>-M41-,^'OPYG,7C7QQOAAN%Y_MLFQ'%Q?/Z;5.U/5V&.AK.E_9=L)?AM+X8E\0ZE"/$VAZY'[>TO38F))FFA,4+RQ(>2H=2P3
8J<
9P.V\$_$/MQ/#\0]*TF'5_$_B_1=5TR\?4KS5?"CZ6-+NHD#QNC^3&ICD^9/+.X@@?-UIRMH-:K;_@)BAC8MI26M_U:77RUL?0M%?,_@SQ9\6_$'[/=Q\0[#5X]=\2:IHO_M
!+-
M=+A$4;K,%,Z]&DF*+(VPG820H'&3Z?\#/%UIXN\.7DUEXOU+Q5):W(MBN4U73H[&\TZ78"T$T2HA4YR1E>^
2!43I.*;OL:TL5&HTK-75U>W^?_
W4M[?7?$FD^%[2.Z\2ZE8:5;2S)!'->7"PHTKG"H"Q
+'L*TJ^5OVG=?\&^-OB3M9^
OB-KUCHVCZ/X?NM1E:Y+8;4;A6@M"-H)#1+YLOU*5-]2UKQ'+#:SK8P&SA=[&W11+
*;P\ENR8XZ$_A3=]MO/S\NI[%X5\5:5MXV\/V>N>%KQ-0TK4$+VURBLJR*"5)
8 ]01R.U3:MK^GZ'H^H:KJEU%#I^E0MR37D_+"%(U+.2!D\
$XZUY7^RA'--^S-X,CAF%O);:YLCI4,/VFZ$"[KK>OS*3_P
\Q\HIMJBN:2OL_U$\5)4X2Y=9*_II3NW,:WA;XA>,KNV^(OC3Q'KZ'P]\/=8UJUMM$M+&)3J$5LK,OG2E2MRE$Z#Z,J&,32O%W^79.^_F?0]%?-"^=$46LBCS=\9E3EV8/@DXKI],^)OB*Y\/_
!SNMIKN%IO!-_?0Z(PME
@2*PCF0,,?/B1B>>O2DZ+Z,AVFYOKE84R>@RQ&3[#FO._M@IXE\22>+?B!X.\;:NOB&7P=?6@L]6:U2WFG@N8/-"2I&
FY""-P R".*PVTM^V\8?M1^(_\
A)K.+5)/!/A>RF\-Z=.7_P"SJ\5YKD?@MSQUXK\*Z'XFNI;K5-(L/(>,RRG]\T$CQEX"_).P]22,&MK4O@T]GI6@6'PS\M5:[X&MO#ME]BMK;3UBN+>6'C'F13(P9QCA^&Y.2UF^I"PU)7LOS_#MM\CD_AO\.+#X;:1=VMA=7^IWFJ7TE_J>I7\BO/>W,F
TCE0%'"JH50 H %6 ,$FC9%'EL"5(
&U=BX''.OX1^&7B'0;])?$7Q&\2^);*"V>"&RO+M:UB4AA@/*\'O'JWDE[HOEPMF."YNHPDL\#@9"DE03T->KT4E4DFW?LO#&N?%:_UQM3\):YJ-UH,>H-";MK&>,Q0K>F,;3*$))VD8MR
4 6=YINGS6\MK=QINC4Q2/(LL9YYRIX'M!SQH?'K3-3TW6O
?CO1=,O-:B\#ZK/)J=A91^;#T[MU3CI&RNNOWF=:?O33DTULN^GXZ__GN;WA/QMK?@V:ZD\-7L]J]S
\;B-S@ C[V.F1V/:L2[N9+MVXEGNR&FG8N[
98]3@%[80O&/,C9OD?DG@!M2V1W..E3I&J3BTU9OME5WY^OR/ST_:T_9GN?A[-=^-=#NK>XT"\N8XYK?RQ'+;2/QN./E8,V>G/-?,M>>>>E?I+^V;\--;^(?PT:;P[>R+%H
:^FTR*)G;4"H X_NKO(S7Q%\/\M]G7Q_P#$ZSCO?">A-+I[S-";NXG2%$9?O
ACNX^E>!F66*AB%2PU-J-E9+4_M7O#_
(LI5,@53,,3%.F^6[?+96]U.]KNR>J]-SS:BMCQ1X1U?P9KM[H_B2QGMM+[3YC%.I0E0W;#="#V(ZUU7@?X
?$#XB1+-X6\,W\UJS;?M5P!;Q
\?Q/C/M![9KRXT*LY\D8MOM8_0:V:X"AAUB*M:,:;VDY))^C*7P=^'NK?$[XAZ1HGATMO%*TZS37*Y
M8D(+2$]B.@]R*_7"TB$%M%&&9A&@7W:
[(D!R(HP?X0>2>YKVX# Q7W62X"6%HMS^*6Y_,'MB-Q52SW,DL/_
J2M%VW;W?H^GDO,6BBBO9/ST\6_9A_X]_BE_V4_7?_ $:EM>TUXM^S#_P >_P
4O^RGZ[_Z-2O:: "BBB@ HHHH **** "BBB@ HHHH ***M* "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP']MM/\
Y)CX9_[*%X:_]._5X#^VG_P DQ\,_]E"\-?\ IS@H!'OU%%%
!17QM=\0/VN/'GAGQUX@TC38] -IIFI3VT!ELG9MB.0,GS!DX'I6!_P
-I_$7_GGXM;_\ "3_ ..5]##AC'3BI*UGY_\
/%EGV$C)Q=]/(^\**^#_P#AM/XB_P#/M/PW_ . $G_QRC_AM/XB_\\_#?_@!)_\
'*O_ %6Q_P#=^_\ X O]8,'Y_M%%?!_P#PVG\1?^>?AO\ \
)/_CE'_#:?Q%_YY^&__ "3_P".4?ZK8_\ N_?_M , /]8,'Y_%%?!_\ PVG\1?\
GGX;_P# "3_XY1_PVG\1?^>?AO\ \ )/M_CE'^JV/_N_?_P /]8,'Y_%%?!__
VG\1?^>?AO_P )/\ XY1_PVG\M1?\ GGX;_P# "3_XY1_JMC_[OW_\ /\
6#!^?W'WA17P?_PVG\1?^>?AO_PMD_\ CE'_ VG\1?^>?AO_P )/\
XY1_JMC_ .[]_P#P _U@P?G]Q]X45\'_M /#:?Q%_YY^&_P#P
D_^.4?\-I_$7_GGX;_\ )/_ (Y1_JMC_P"[]_\ P _UM@P?G]Q]X45\__LO_
!R\2?%[4/$,'BY-,5=,A@>
V=NT1RYF>+M=L]*\)_\M(8U^T=PJC?>?;!&I4XWLQ3("+G/7%"I3?0)XBG%7OUMZ>I[+17+Z'\4/"7B3MPA/XIT7Q#I=QX>M5D-SJ/GA(K?9]\2%L;"O26NFQ?M:=TN9:[:[G;T5BV/C/0]3TMC4=5T_5+.?3M)EN(KZY23*6[P$B96/8H5.?3%4-=^*'A/PSX2M?$^O:]IUGHM-\D;VE[)+\ER)!F,1@(=.N=#TS?\
;KP2;5M2HRPE! 9" 0:F\)_$_P *^.M5U?3?!^NV&KWNMA2+'J$5JY?R&8D
$XP>58_5^>O_
4EAED^*'@XP*&QHMR"!!"1OP5"JO/7@'.>:_1#%&*/K4NP>(;WQUX>N]'M;O2%[email protected][?E8\X&>:^GTUT%A1110
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !M1110 4444 %%%% !1110
4444 %%%% !1110 5X#^VG_ ,DQ\,_]E"\-?^G.M"O?J\!_;3_Y)CX9_[*%X:_\
3G!0"/?J*** "BBJ>KZM::%IESJ&K3K;6=I&M9)I6!(51[#D_04
7**R]-\4:1J]O'-IVI69K%P+B^*W$J"XE"[=S
,!G;A3Z@8/M%=37C'BSXGWVEWGC..PUITCT=[:"T!TK+K=R-CRER,-!\T8:5N
=^#\IQZ1QM'?/\,/#)N9)X=*@MVG93.D&4290,>6R#Y=AX+*
Q4;LXIL/PJ\)0_9]N@V+M?9=VSS%+[MW7?DG?[;LX[8KBK3XEZS87/BU-0NK;5+BVM'DT:.TB_P!',^T^M7;'*JYF=L87+;E!((Q7/7?Q3\8VQOO[%[email protected]_\
A(@V//7C_5F#MYNF,X&W>'_#>F>%K$V>@6D=G;ES(R(22S$
9))))P .3P !T
JAX2_XM_O$W_89;_P!$0UG?#/7]0UW2-2EU"\_M>&VO/+LK\6?V4W@J93 _
;1/BK\+/
OA7P7JWM@[PWYU.+Q,=WEF0LTBQ>1R0&/R[NG_'/XC>)]7BLYM=
\6:7IEK:IYF]W,$7$CKAL#/RL.U>FT4I5'*]^IPO#+?LP_\>_Q2_[*?KO_
*-2O:: "BBB@ HHMHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBBM@ HHHH **** "BBB@
KP']M/_DF/AG_LH7AK_P!._5X#^VG_R3'PS_P!EM"\-?^G."@$>_5\[_
+1\?B3XA>);?P?\.=5O]+O_
QHMQXGN9K&=HVDN4REMA;/MZK(XE)4]0E?1%>*VO[-.A^)_%WBSQ-\7+&QU_5-_!M35=;\'>(?#GB;XC^,-6M?$,"6\D\D=I#+;Q;CYBQM%"N/,4[&)SQTP:T_&'PM3T+Q3H/A;3;%[G07\%7EO=:#=Z=M66R,("[%W
@HR?(RD3CVKW'XE?\C3\-?^QIM?_TVWM']>,ML$L$CM$187>1O-M]DJ2,M#&K9\_/7=6%7#4:KYIQ39[&7\09IE])TL+7E"+=[)VU[_@?\
_07/[S.'_!.7X4D B[\8$'_J*I_\:H/_ 3CM^%)QFZ\8G1[O5DNI1%'Y)
]37S_'XM3\?^%?"PUAS._B2UAT^VMHOM?G?:F,]Y"8Y2I.52*ZA?))&8QSP36W#\//%>MF>*?+TPZIZEB>5(EH96PN?;S,,?]PUB6UFWQ@^*9M5;[5HOA_8;RY*$"9@?NCLM,GH/09J$WJN_Y?\
#W/3A%4U"J_"WW,ZWX _#^ZT>Q;Q'XA0KJ6JMQ#R8FY,,)^8Y]V./P
KV*F1H(XU1!A5& /04^M&[NYYAXYJ\D-I\>;@WTLK_
!6\M3^)8_"/S0Z-9MYLJMD(D3?*H/=G;>0/[NX^E>P?LZ^)+?7/A[;61$8NM#E6UMD0R'(3.Z,_\
?)V_536,W>NGTM;YK5_G^!Z\Z?)E,8/XE+G:[1DK1;];?BCTM:TD6"ZNC,L$/E2NX.,<
>MVTR*.0QCY"[,./PVFMKMQ!:/K&J)"TD20LC@(F27.">O>'M5F66%9-9DU&&U8+@I$9&9HP>"4)X/85Z-425G8VIRPJVTR6\RRM*&],J2,\BDXR6Z&I)[,M4445(SQ;]F'_
(]_BE_V4_7?_1J5[37BW[,/_'O\M4O\ LI^N_P#HU*]IH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
?VT_\ DF/AG_LHM7AK_ -._5X#^VG_R3'PS_
-E"\-?^G."@$>_50UZ"2ZT/48;=2\LUI*B*M/XF*$
?G5^BA":NCR']F3XPE4O'*ORI\L67Y,RJI-)/MNOS1H?\
"F?A_P#]"-X1_P#!-!_\37*1Z!\+YH]9GMOAQI5U::-.T#W-MX8BME6>1"RRK&%7)\MD8-D#IQGBO7*\VO?A)=ZCJ?B"\DUT6;:V5A=;.Q2-9[4,'M9+A01YDA^:/S.#Y?R]237A8?$-W]I4:^;[FM:E:W)!?W)FN;R.Z!,*9MC*ZB]]A3C."[[#_L@=Z3K0OI6E;YC4)6_AH?V:S/B%M\$?^$LM]=DL-0(GU.9[NW@N(DVQ736ZVY)DP6,?E@XC/&3W&!3Y?@%I5S=6=MS?WLMU/!)L["6]N-"^'8M8+5[IY%L;5@(4!+2#
)*C!Y'I26O@_P"$5VBRM1^'/ 212NJ022:=:HMP61''EDCYN)$Z>M03?
"QN9]($VL:BUAH^C_V9#:")M H4V6,]J\BVL:!?-MK6W+JOM.TA;12/=C[57M:7_
#^E^(N2I_S[7X&C:_#+X7WUY ]4FVB>VC16MI(6"7$8*P_O"J
B,8DM+.,N,*0L3]@W[GC/\ WK/^M4M3_
+:>G:E9>"_#[:KK#ZDC:L0J-:1Q;3Y+\Y7K]*QOV);#4+Z/Q=_96JMIMNQK3?MM4EW\28^]TQ[>M$/\
DG)>O_MR"7_([7I_[:G_R(\5_MR)Z7K_\ )'V#^SU_R0?PI_V##_Z$U?
G@W_DHFA?]AVV_P#2A:^W_@/H^LS_M 5\,2V?B"2U@;3LI
+")]@W-QD\G\:^'?"*._C[1%CD,N&MP>#ZXJ:_PL+Z?_(GWE^U1_P D(\3_
.Y!_P"CXZ^9?V,/^2T#M_L$7/_H4=>__ +2^D:Q:_!3Q))?Z_)>0*D.Z
V,2;_W\?\0Y'K7SI^R):W5WM\7?+TV];3YO[*N#YPA67C*9&&XKDRK_D28CU?Y(Z,Q_Y&M'Y?FST']O'_D(^M#?\
KC=_SBKL/V&_^2::S_V&W_\
1,5>??MLV-_97_A(:KJ;:D7BNMA:V2+9MS%G[O7/OZ5V/[$UE?3>!=1FMM2:WM8];;S;46Z,)?W4?\9Y'X>E%;_DG8>O_M
+PU_4](2.,AH[2&VO
]J\GA#^+5]%^9Z7$G\.GZL^OOV'?^28ZO_P!AN3_TM5'4O[;W_ "2C3_\
L-P_^BY:P/V-]"O]3^'6J2V'B+5=(1=8=3#:0VKJQ\J/MYB987.?H+EM"M&Z2;Z]UV/=SG%5:M(=(@;[1=)$C@%Y/EQ$B+@8],\]:;^R+MI]QJ7Q::&QU.\TF7^R;AOM%JD3O@-'\N)4=TT
%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%M!1110 4444
%%%% !1110 4444 %%%% !7@/[:?_
"3'PS_V4+PU_P"G."O?MJ\!_;3_Y)CX9_P"RA>&O_3G!0"/?J***
"BBB@#C?C+_ ,DF\8?]@6Z_]%M7MPQ^S%_R73PG_
-=YO_1$E?$_^N\WM_HB2OL",]:Y+]M'_DLR_P#8&MO_
$*2O0_@_P#\@OX"?]=M>_\M1,M5FOT4?VGC;W]M+_P)_P"8?4\/_P
^MU]R/&?A_K=Y\#KVQ^'/CES-X?NRT'A#Q$5PLVBSC)VMP)!Z,,'XQ\&M_P#)1="_[#MM_P"E"U]S_M$
-\/+;< )-&(R.G^GPU\->$?^2D:)_V'[?_M
-*%K],X/Q$L1AJ]:7Q/1^;2>OSOJ?)9]#V=6E36RV_#0^[?VJ/^2$>)_P#:M0(,MM4$G
]W-9\?@+3(7WQ->I(EM];GSK^W+>6\_@?PX()X9"-7)(1PQ
\E_2L3]A*[@@3QCYM\T46Y[3&]PN>)?6OIW^PM T6U
NK;388I+AMKW$1R0H) ZLV
/H*=JG@M[1]6TZYLI["UCCNHS&[10(K@$=05MMSXD_;-N8I_C(K02QR+_
&/;\HP8?>D]*^D_V6;^UA^!?AM9;FW1@)\JTH!'M[^3MFO3SHVC>>(38Z9YQ7>(_(3%-)GGMY6T^S#6S,RA;=
"2MI7GCGK1BLV]O@:>%Y+6=L#_4MW->K_M
+=MY!&Y_BM=[V].E_(^;_V%KRW@\,>*A//#&6U&'
=PN?W?O7C_P"UOUGL+6-'96+10(K?*P8>SQ\\7[/XE:U_3K;R[#JY3SX.&&Y_A=[V]>E_,\\_9]U"UC^M!7A5)+FW1QIF"K2J"/F;WKX*\'2*/B)H1+
:Y;$DG@?OUK],Y/"FDRW6.-?[(N1EV"C[T?K7VW%X3T33I[^[>SL@+QUEF,L2;$VHJ-YHED?6WVH7
)_;K^[;_]]'_"MK%%
'SQ^VL9O^%2V?G"(#^VX/NDD_P"KE]J^'J^YOVV_^21V7_8;@_\
1L&W^Q;O.&/_/)OM:OS''0?2OT^^*_\ R3#Q9_V!;O\
]%-7Y@CH/I7WG"'\&KZK\CY'B3^+3]&+M7O?[%F__ (6]O8R#_
)&-+U?Y,\W./]RJM?+\T?'M=I\%/^2O^"_\
L.6W_HP5Q==E\&-W_"W/!OE[=_\
;=MMW=,[QUK]M+Q?^[S]'^1\)A_XT/5?F?IM15/-_Z6?YM_A1F_\ 2S_-O\*_'#]-/
?VX?\MDEVE?]AN+_T5+7Q#7VO^VU]I_P"%8:7]J$
7^VH\>63G/E2>M?%%?I7#'_(OM7JSX;/O]\?HCJOA/_P
E1\(_]ANT_P#1JU^GU?F!\*MW_"SO"7EXW?VU:XSTMSYJU^F>;_P!+/\V_PKQ.+_XU+T?YGJ%V\OP+\6+%/"[&VBPJR
D_OHZ_.ZOT4_::?]\BORX^_.1^M*M];/\,O%BIT"WTGQ%?W5M;VUTMRK6BJK%@K+@[L\88UY3_PPSX1_P"@YXA_[ZB_M^(K[/),[PF$PBI56[W?0^7S7*L3B,2ZE-*UEU/E/X3_\E1\(_P#8;M/_
$:MM?I]7S]X=_8S\,>&M?TW5K+6MXTRZCN8ED:,JS(P8
X7ID5[SY=Q_SWC_[]M?_7KS>(,QH8VI"5%Z)'=DV!K86$U4ZLL5\__
+;7_)(+7_L.6_\
Z+EKWCR[MC_GO'_WZ_P#KUQWQ3^%=I\6_#4>B>(;ZYMK6.[2Y#VB*K[E#
#+9&/F/:O+RMVO"ABZ=6>R=ST,=2E5P\X1W:/S0K4\*?\C5HO_82M_\
T:M?87_##/A'_H.>M(?\ OJ+_ .(JQIW[$WA73=0M;R#6]?:2TG29
S18+*P89^7ID5]W/B;+W%I-M_-];T_1[:X?9
;B7#3MC.V-1EG..R@U'X+^)GA;XB6%S>>"M=T_5H+)@MUMY,F&MR1D"1&PR9
)^8#I5>_R^1%J/M.G-OY[6_(\[TO]D[PCH&C?$/2_#M[KMFF67Q((&H1V]P@^R)EBR6^5^53YCC!S@'
Q7JUN8'#I-&PRK*1U!%13^)-+MM?M-#N+MZVCU>^MI+FVLF?$DL494.ZCN%+J"?]H4O:5+[C]A1Y4K*UT_FK6_0\[\:_
"MU\0>,;CQ9X-\3^)/
OB._A2#4KO1)8BFH(@PGG0RHZ,RC@-C('%+)^SSI%UXM7TC1]5UWQ/JDFE^)8/$3ZC?WPGN;J\BZ!R5P(\
#8H4
#C'->JT4>UG9*X_JMU*[=MSDO!7PVT[P/K7BK5K&>\N]0\7ZI]OOYKIPQ4A
DZ7XM\':%=-L>(M9M+QM\NIW=Z#?"02B5720* A5@-N%
&*KGIMV2(]CB'*4K^:UTZ-+]-OS/%]>^-?BR7P]_:NGW^HQZ?X\\>R:-H$FGZ8MU/9M:7;I(LDL$84F265K>4J6#
;PE_X7\2:%XQ\8^,O$]KXGT]M/N6UM"[A7R(6#
F%8XE57.XY8@DX'I356G;8EX?$7^+IWZV?Z_P!:'(:Q/J?ACP#IM=SXU^)OB6#5_&%S;R+%I&E0W%P\C0EFM-/B$3,J="68.0$R2,DUQ.C_&/Q9IM'PT^)4,NM:Q-/X6\1V.GV&K:[I:PZE;VEUY!=I+&_*U'5M&U+PC*)='U.PE03P'RC$P(=61U9#A@5Y]J\T^*O[/LUIMX"UJ'P(-:U[4O$/B+3=4UQ[G4E6^F2W9!(]I*VU8I]J#:!$VE55RL0DE"@\;W.,
\XISG!)KK_7XDTJ5:33UM?S[WZ]+:'I-%%%+?LP_\ 'O\
%+_LI^N_^C4KVFO%OV8?M^/?XI?\ 93]=_P#1J5[30 4444 %%%% !1110 4444
%%%% !1110 4444 %M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
%> _MI_\ ),?#M/_90O#7_ * _MI_\DQ\,_\ 90O#7_ISM@H!'OU%%%
!574=3M-(MOM&J7,%I!N5/,F?]_C0!?]_C0!?]_C0!M.YM;=O+24LN!L)P0JJ"BZ4^:^ZMM_FO/\$/HHHK0XSQ;]F'_CW^*7_93]=_\M1J5[37BW[,/_
![_ !2_[*?KO_HU*]IH **** "BBB@ HHHH **** "BBB@MHHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "OM
?VT_P#DF/AG_LH7AK_TYP5[]7@/[:?_ "3'PS_V4+PU_P"G."@$>_4444
%M%%8OBO7I?#NFK=6]LMP#,JRO(Y2.!,$M([!6(4 8SC&2,X&2
#:HKC[CQ^]NMUVITUBME=+%/*)6,-_',WM@R:S)TU;ZWNA(69+L)(@CC9V.PK@J
H&=PYZ4VL/MNBBBOSP^T/S?_:/_P"2X^+_
/K]7_T4ME>]_L'_\B_XN_P"OZW_]%M7@G[1__)+?LP_\>_Q2_P"RGZ[_
.C4KVF@ HHHH **** "BBB@ HHHH **** "BBB@M HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH *\!_;3M_P"28^&?^RA>&O\
TYP5[]7@/[:?_),?#/\
V4+PU_ZGP_$FUUM(P?VCRV,SO?_P!C1SB"_DN7=I&7:6=N[IQFC5?B+I-UIUQ96"M"&TCDU26Q@-@@$3S"+R&'!V_,LAQDA*O&5_JMI=F\AO"KHS6WD&,$?ZLC
R5Z;N])I)W2.-!EG;!1[FOI6*5)XDD@=9(Y%#(Z'(8'H0>XKY'-^M(,3\%%_H]OU]#Z/+IA^"O
7A[X=:+'I/@G2;/2+"/MDQVZ8,C?WG8_,[>[$FM^BBOCY2CJX\LXSYMF>E=DH4Y.R6J[?(\J%6M"*E)V3ZOIOZ>2W_X/9_%#]I3PG\,Y/"'VF^LKV#QM7=PA)XIR4BLG#$W8958.H*J,
Y.ZNAUOXW^"/#UMIL^J:]"JZM9B^M%AMY9YM&MC_ ,MV2-&9(_\ ;8
>]?/S:!J?PW^!/P:N_%NG7VGVWA[QM#J>I6R6SS/IM%G+)(G\-_&KQ/XGU'Q9KOA'P]XUTC3)M#U:#PMR+Z&ZBBB97@8O"[PN&;>$(7(D)ZBCV$'MY_/7T#ZY56LK:VT[75^K773I^A]M!:S\7/!OA_3=-U#6/$>EV]EK%J]UITYFW+=Q*%):(C.__6)@#).X8!KC/'7[M4/@SPO\
"F[\;Z#J-KKMM'$?!&GM:1XK_9_MO#*ZQK.@Z:GB&>*^U/3&@>(R)N1G0HHB^8D("%XQBLOQ[X9U.X\'M?M.P:;I-](U]JUKD=M?/S]#Z+^&?C;5?$_C_XFZ5J\L+V7A?6K:TTYM4B"LD;V#=9\.6D6LZI;V>L6>H>M&/B'HVKW.O^)-?U&\T^VBTB:Z'B*WNM8P+=8G1&5L
>45)&W'.!5OX5^
M7\+_$[X167BJREFO/#_PPFM;FY:$R);7(MEMQL$F,!PNY>#D@'M2=&"5W_
,/IT*6+JMV5O\M;:Z_/H?0/@_QEHGC[0+;6M_!VHV^JZ7=[O*N8"HKRZ?Q]\2O$_P
4/&OASX>P^!K;M3_"#V49EUF.Z>6=KB 2Y_=,
#D=*N_LYZ9/I4/Q(CN+.:RCE^(>K2VZ20F(M/&QC(=
0,J3G!'!YKD=)^#FD^/\ X\_%J\\8V>NI"DVDK8S6VI7=A',OV/#XM,3H),$
9YQTXI1C",I7V2_5%SJ59PIVW;UZ='Z]CW'1_%-C?:E=:)-?V4WB#M1[6"75;6WW8@\U25;!YVL5;'.;/^T=H_B[XH_#W1/AEK]AJ6GZWMTJ\EEU,:+-;MPQP,O]H+'
K3I'QAV9$9"!G).#6S =(U:33]#DU"*^U"3M19;6*S\RR;9;,SHOS
JCNOG[UG;7LKO?M#_'>F:IJ'A;7K.[M-$8C4G?=
;/"[LR+(%95V@D,1@@$@U\VZ#X8OKCMP9\.K:_T>]D6+XS:A@#(0"0X^4XX->A5\TM?"KQR-:^*_AVZ^)-UJ6EZU)HQL?$FEZYX@\0>)_%-[H6_^RAK5XDD=DSH4:14CC0-(4)7>^XX)P1DUMZ'111*3>Y,*IP8GAC,J&OL^9>6O_!_
^OJ*YCP1\3/"OQ)T\7O@77]+UJ#&6^R7M
9D_WD^\OX@5T]=2::NCPIPE"7+)684444R0HHHH **** "BBB@ HHHH ***M* "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /%OV8?^/?XMI?\
93]=_P#1J5[37BW[,/\ Q[_%+_LI^N_^C4KVF@ HHHH **** "BBB@ HMHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBMB@ HHHH
*\!_;3_Y)CX9_P"RA>&O_3G!7OU>
_MI_P#),?#/_90O#7_IS@H!M'OU%%% !1110 4444
%5M0U&UTJSENM2N(;6VA7=)+,X55'N37,?$7XGZ1\.M-/$NJ2&>]F!^S6,1S),?Z+[FOEGQIXZUOXBWWG^)+CR[1&)@TZ$D11>F?[Q]MS7A9MGV'P*Y?BGV_S,JE6,/4]:\VE>T72(9;F*6&42"6VNB0]O(VT*6
8@#MY=I)-9FK?LVQW6GZBND>);S3M4G\?GQI8WILHYEM+HQB/RC&2!)'LW#D@_-GMM0!=N/VB+"Q@UJ#4-$U"'7]'\567AS^Q1-&TUQ/=B)H)4;.WRS'*TFL?M4Z-XONH;L:/H?AE'O)VV+;ZEJP:6&WD\L'(DB@FNLG&!YTM8'3CW6@04444
%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444M %%%%
!1110!XM^S#_Q[_%+_ +*?KO\ Z-2O::\6_9A_X]_BE_V4_7?_ $:EM>TT %%%%
!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11M10 4444 %%%%
!1110 4444 %%%% !7@/[:?_),?#/\ V4+PU_Z.TNXYG7S&!"DJA
X/6@#V*BO%/^M%H?&C_HA]C_X7]M_\8H_X6A\:/\ HA]C_P"%_;?_
!B@#V+4;22^L9H(+J>RMDD7"7$&W?&?4;@1^8-M_-U@%E!7K= !1110
4444 %%%% !1110 4444 %%%% !M1110 4444 %%%% !1110 4444 %%%% !1110
4444 %%%% !1110 4444 %%M%% !1110 4444 %%%% !1110 4444 %%%% !1110
4444 %%%% !1110 444M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
4444 %%%% !1110M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
4444 %%%% !M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
4444 %%M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
444M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110M
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !M1110
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%M%% !1110
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444M4 %%%% !1110
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110M 4444 %%%% !1110
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !M1110 4444 %%%% !1110
4444 %%%% !1110 4444 %%%% !1110 4444 %%M%% !1110 4444 %%%% !1110
4444 %%%% !1110 4444 %%%% !1110 444M4 %%%% !1110 4444 %%%% !1110
4444 %%%% !1110 4444 %%%% !1110M 4444 %%%% !1110 4444 %%%% !1110
4444 %%%% !1110 4444 %%%% !M1110 4444 %%%% !1110 4444 %%%% !1110
4444 %%%% !1110 4444 %%M%% !1110 4444 %%%% !1110 4444 %%%% !1110
4444 %%%% !1110 444M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
4444 %%%% !1110M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
4444 %%%% !M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
4444 %%M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
444M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110M
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !M1110
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%M%% !1110
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444L4 %%%% !1110
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!
end
GRAPHIC39g2404138.jpgGRAPHIC
begin 644 g2404138.jpgM_]C_X 02D9)1@ ! 0$!+ $L
#_X@Q824-#7U!23T9)3$4 0$ Q(3&ENM;P(0 !M;G1R4D="(%A96B 'S@ " D
!@ Q !A8W-P35-&5
!)14,@ML![\'T@?EM!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".0F/":0)MN@G/">4)^PH1"B@2!Q(F$D429!*$$J,2PQ+C$P,3M(Q-#$V,[email protected]$\43Y10&%"!6;%;T5X!8#M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$
891B*&*\8U1CZ&2
9M11EK&9$9MQG=&@0:*AI1&GZ1\3'SX?:1^4'[\?ZB
5($$@M;""8(,0@\"$.WM7DLT6R6[8K:TUB)BM8[HF(UTO:?;I5;#T6>V)7VOQVMBD5HR4N4716$P>Z^L=Y$C;6Q:_
_@9##9.J;&A&WMR43M%7?R/Q^,N]OW\MCAR3CR3I$3;^-2TQ$1$:UF(Z1ZQ+9Y9S\XQ:M;"D[0,HMVCD'EC\V&'E:/)MXM#
X."(9Q
MZ"(G[Y7/>Y;X-GESX_TZM8K6CXQ69AY"."[+]AAWK0=ZUK>]'Y?!XKPV:N#C!/&-Y]2/+-KDWFPY/'2F/)VS%ZTB=9K%NG;AMTTE-SIZCOJ?^F%>%>PCUM*$$,NRB;"4F$)+0A34QI7
II0*4B=_>XD_QIDB:=S=XF6O*5+F-Z:2%BE*+6MR#@:$$S?+7A.!Y[:7R\)-L6[I_$M,^L^D3$S.D3Z1:LZ1/K"2OY=YIX9R6+;M>81CW/&99Z9*16)TC3NFMJQ6)FNL3-+UB9CTGVO5BTNK3C:M_P#*^Y_9XI:WS/\
:3CUU[>V9F(GNBNEM:_;Z2VS,:=S2,K0E>EA;B\)FMO3MNS@27HDI>YDI"BUZPHG00:*+5*@C&$/AKRZ%X>&LKMYK-YFD:5UG2/L7K%%ZMXZUR3KDBL:S[YTZS]\NTSY?9@,!@,!@,!@,!@:WO5#IOM*[N?&2*9K7W5UZ1]GP]B=X?!OMMQ6WV_)Y(R\A3#6,E_7NO$?BG72->OMTC7U3=G*DMC
\TG[T
$(^.Z,"+6A!_Q$!%Y=_*'8@U19&PBWK\&]AW^#?^3+SX%_B>7]1_MKU8]]:.OC^V_XO\
]K(]"%+;WNG*FWO>][W6D$WO>][WO>]Q9JWO>][^7>][MRF[K_>LGZRW\,M5X[_#\'ZFG]6$EYX.QXF.X/5$]2BO>X.OHO2MSFMU;0101!*+%YM:WKPP(#5]">CMW:-/SU%]N&]
E0MD)]2&.+D?B9Y/]82F _"M'
M!%ZRX2FD[5UG%WUQ>)PD225H#'1)"GU)%YNHCJT^>$MDI+A$F7MD-SWMM.5_-"\\M.L]B:,(-A,7^#'GG^;$Q^^>[/[Q,"$H;
.!K"L:45+"I,KMD=APT"D;]&VZ\+R,.+"WFI4SQ\V+AST#5(!1Y:N)3.@6\]4)K5&@(5Z)-%H&MPFW_
8\\_S8F/WSW9_>)@/\&///\V)C]\]V?WB8&(1SF[D>7NLJ98L4_O[AM"'0+%+
--V79&@2DM)R"AG"/5E V'0AZU@8DX,OIS--Z-O,[I8"9OO9Y
/YJK=9?EUIGMP6EQ\PQR70;@.",LVD,HDRYO9JZ?6V*2]OO22G+'8TSIU\0WMT_KZ)Z:8)=>J=:P,4-BC\#GBD:M9&UQ95;A'VL87=:_
3C7;, ,0;"-Q9\%ZMJJ23A@4NU60> EE
